Nuvation Bio, Inc. (PANA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1251151,
    "name": "Nuvation Bio, Inc.",
    "stock_name": "Nuvation Bio, Inc.",
    "full_name": "Nuvation Bio, Inc.",
    "name_url": "stocks-analysis/nuvation-bio-inc",
    "exchange": 207,
    "exchangecode": "NYS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "8.66",
    "chg": 0.15,
    "chgp": "1.76%",
    "dir": 1,
    "prev_price": "8.51",
    "mcapval": "1,198.02",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US67080N1019",
    "curr_date": "Dec 16",
    "curr_time": "",
    "bse_nse_vol": "3.88 M",
    "exc_status": "Active",
    "traded_date": "Dec 16, 2025",
    "traded_date_str": "2025 12 16",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/nuvation-bio-inc-1251151-207&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Nuvation Bio Hits New 52-Week High of $5.55, Up 81.38%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nuvation-bio-hits-new-52-week-high-of-555-up-8138-3659213",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/NuvationBioInc_priceRelatedfactors_3659213.png",
        "date": "2025-10-30 18:53:16",
        "description": "Nuvation Bio, Inc. has achieved a new 52-week high of USD 5.55, marking an 81.38% increase over the past year. With a market capitalization of USD 1,198 million, the company faces challenges, including a negative return on equity and a notable debt-to-equity ratio, while navigating the competitive biotechnology sector."
      },
      {
        "title": "Nuvation Bio Hits Day High with 10.48% Surge, Showcases Strong Intraday Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nuvation-bio-hits-day-high-with-1048-surge-showcases-strong-intraday-performance-3649343",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/NuvationBioInc_priceRelatedfactors_3649343.png",
        "date": "2025-10-27 17:43:14",
        "description": "Nuvation Bio, Inc. has seen notable stock performance, with significant increases over various time frames, including a 110.87% return over the past year. Despite facing challenges such as negative results in recent quarters and declining profits, the company's market capitalization stands at approximately USD 1,198 million."
      },
      {
        "title": "Nuvation Bio Hits New 52-Week High of $4.87, Up 67%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nuvation-bio-hits-new-52-week-high-of-487-up-67-3649304",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/NuvationBioInc_priceRelatedfactors_3649304.png",
        "date": "2025-10-27 17:04:13",
        "description": "Nuvation Bio, Inc. has achieved a new 52-week high, reflecting a strong one-year performance that significantly outpaces the S&P 500. With a market capitalization of USD 1,198 million, the company faces challenges, including negative return on equity and a high debt-to-equity ratio, while pursuing a growth-focused strategy."
      },
      {
        "title": "Nuvation Bio Hits New 52-Week High of $4.32, Up 43.1%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nuvation-bio-hits-new-52-week-high-of-432-up-431-3641290",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/NuvationBioInc_priceRelatedfactors_3641290.png",
        "date": "2025-10-23 17:14:54",
        "description": "Nuvation Bio, Inc. has achieved a new 52-week high, reflecting a strong one-year performance that surpasses the S&P 500. With a market capitalization of USD 1,198 million, the company faces challenges in financial metrics, including negative return on equity and a high price-to-book ratio, amidst a competitive biotechnology landscape."
      },
      {
        "title": "Nuvation Bio Hits Day High with 15.63% Surge in Strong Intraday Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nuvation-bio-hits-day-high-with-1563-surge-in-strong-intraday-performance-3585931",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/NuvationBioInc_priceRelatedfactors_3585931.png",
        "date": "2025-10-01 16:22:46",
        "description": "Nuvation Bio, Inc. has seen notable stock activity, with a significant increase on September 30, 2025. The company has demonstrated strong weekly and monthly performance, alongside a year-to-date rise. Despite facing challenges with consecutive negative quarterly results, its one-year return reflects resilience in the competitive pharmaceuticals sector."
      },
      {
        "title": "Nuvation Bio Stock Hits Day Low of $3.00 Amid Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nuvation-bio-stock-hits-day-low-of-300-amid-price-pressure-3574376",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/NuvationBioInc_priceRelatedfactors_3574376.png",
        "date": "2025-09-26 14:27:30",
        "description": "Nuvation Bio, Inc. has faced a notable stock decline, reaching an intraday low amid a challenging trading environment. Despite a positive monthly performance, the company's long-term outlook is concerning, with significant declines over five years and ongoing negative quarterly results, raising valuation concerns."
      },
      {
        "title": "Is Nuvation Bio, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-nuvation-bio-inc-technically-bullish-or-bearish-3548224",
        "imagepath": "",
        "date": "2025-09-20 20:12:37",
        "description": "As of 3 September 2025, the technical trend for Nuvation Bio, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating positive momentum. Daily moving averages also support a bullish stance. However, the monthly KST is mildly bearish, and the Dow Theory shows no trend on a weekly basis while being mildly bullish monthly. \n\nIn terms of performance, the stock has returned 19.17% year-to-date, outperforming the S&P 500's 12.22%, but has underperformed over longer periods, particularly in the 3-year and 5-year comparisons. Overall, the current technical stance is bullish with moderate strength...."
      },
      {
        "title": "Is Nuvation Bio, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-nuvation-bio-inc-overvalued-or-undervalued-3544332",
        "imagepath": "",
        "date": "2025-09-20 18:43:35",
        "description": "As of 5 August 2024, the valuation grade for Nuvation Bio, Inc. has moved from does not qualify to risky, indicating increased concerns regarding its financial health. The company appears to be overvalued given its significant negative financial metrics, including a Price to Book Value of 2.01 and an EV to Sales ratio of 35.57, which are considerably high for a company in the pharmaceuticals and biotechnology sector. Additionally, the negative ROE of -43.17% further underscores the challenges the company faces.\n\nIn comparison to its peers, Nuvation Bio, Inc. has a worse EV to EBITDA ratio of -1.90 compared to uniQure NV's -6.6289, highlighting its relative inefficiency. The stock has experienced mixed performance, with a year-to-date return of 19.17%, outperforming the S&P 500's 12.22%, but it has significantly lagged over longer periods, with a 5-year return of -71.18% compared to the S&P 500's 96.61%. Thi..."
      }
    ],
    "total": 12,
    "sid": "1251151",
    "stock_news_url": "https://www.marketsmojo.com/news/nuvation-bio-inc-1251151"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Nuvation Bio Hits New 52-Week High of $5.55, Up 81.38%

2025-10-30 18:53:16

Nuvation Bio, Inc. has achieved a new 52-week high of USD 5.55, marking an 81.38% increase over the past year. With a market capitalization of USD 1,198 million, the company faces challenges, including a negative return on equity and a notable debt-to-equity ratio, while navigating the competitive biotechnology sector.

Nuvation Bio Hits Day High with 10.48% Surge, Showcases Strong Intraday Performance

2025-10-27 17:43:14

Nuvation Bio, Inc. has seen notable stock performance, with significant increases over various time frames, including a 110.87% return over the past year. Despite facing challenges such as negative results in recent quarters and declining profits, the company's market capitalization stands at approximately USD 1,198 million.

Nuvation Bio Hits New 52-Week High of $4.87, Up 67%

2025-10-27 17:04:13

Nuvation Bio, Inc. has achieved a new 52-week high, reflecting a strong one-year performance that significantly outpaces the S&P 500. With a market capitalization of USD 1,198 million, the company faces challenges, including negative return on equity and a high debt-to-equity ratio, while pursuing a growth-focused strategy.

Nuvation Bio Hits New 52-Week High of $4.32, Up 43.1%

2025-10-23 17:14:54

Nuvation Bio, Inc. has achieved a new 52-week high, reflecting a strong one-year performance that surpasses the S&P 500. With a market capitalization of USD 1,198 million, the company faces challenges in financial metrics, including negative return on equity and a high price-to-book ratio, amidst a competitive biotechnology landscape.

Nuvation Bio Hits Day High with 15.63% Surge in Strong Intraday Performance

2025-10-01 16:22:46

Nuvation Bio, Inc. has seen notable stock activity, with a significant increase on September 30, 2025. The company has demonstrated strong weekly and monthly performance, alongside a year-to-date rise. Despite facing challenges with consecutive negative quarterly results, its one-year return reflects resilience in the competitive pharmaceuticals sector.

Nuvation Bio Stock Hits Day Low of $3.00 Amid Price Pressure

2025-09-26 14:27:30

Nuvation Bio, Inc. has faced a notable stock decline, reaching an intraday low amid a challenging trading environment. Despite a positive monthly performance, the company's long-term outlook is concerning, with significant declines over five years and ongoing negative quarterly results, raising valuation concerns.

Is Nuvation Bio, Inc. technically bullish or bearish?

2025-09-20 20:12:37

As of 3 September 2025, the technical trend for Nuvation Bio, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating positive momentum. Daily moving averages also support a bullish stance. However, the monthly KST is mildly bearish, and the Dow Theory shows no trend on a weekly basis while being mildly bullish monthly. In terms of performance, the stock has returned 19.17% year-to-date, outperforming the S&P 500's 12.22%, but has underperformed over longer periods, particularly in the 3-year and 5-year comparisons. Overall, the current technical stance is bullish with moderate strength....

Is Nuvation Bio, Inc. overvalued or undervalued?

2025-09-20 18:43:35

As of 5 August 2024, the valuation grade for Nuvation Bio, Inc. has moved from does not qualify to risky, indicating increased concerns regarding its financial health. The company appears to be overvalued given its significant negative financial metrics, including a Price to Book Value of 2.01 and an EV to Sales ratio of 35.57, which are considerably high for a company in the pharmaceuticals and biotechnology sector. Additionally, the negative ROE of -43.17% further underscores the challenges the company faces. In comparison to its peers, Nuvation Bio, Inc. has a worse EV to EBITDA ratio of -1.90 compared to uniQure NV's -6.6289, highlighting its relative inefficiency. The stock has experienced mixed performance, with a year-to-date return of 19.17%, outperforming the S&P 500's 12.22%, but it has significantly lagged over longer periods, with a 5-year return of -71.18% compared to the S&P 500's 96.61%. Thi...

View All News